Drug intelligence / Profile preview

CanVirex02

Development stage: Preclinical
Lead developer: CanVirex
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intratumoral

Overview

CanVirex02 is an investigational oncolytic virus therapy being developed by CanVirex. It utilizes a measles virus (MV) vector platform, specifically derived from the attenuated Schwarz vaccine strain, to selectively infect and lyse tumor cells while stimulating a systemic anti-tumor immune response. As part of CanVirex's portfolio of cancer immunotherapies, the vector is engineered to express therapeutic payloads that modify the tumor microenvironment to enhance immune activity. CanVirex02 is currently in the discovery or pre-clinical stage for the treatment of solid tumors.

Targets

CD46 (CD46 Molecule)

Beyond the preview

Go deeper on CanVirex02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanVirex02.

Explore the full profile